Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-08-27
2010-11-02
Davis, Zinna N (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S953000
Reexamination Certificate
active
07825109
ABSTRACT:
A compound having an ability to bind to an S1P receptor (particularly EDG-6, preferably EDG-1 and EDG-6), for example, the compound represented by formula (I) of the present invention, a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like.wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1is a substituent, and wherein m is 2 or more, R1s are the same or different.
REFERENCES:
patent: 2003/0139597 (2003-07-01), Xue et al.
patent: 0635492 (1995-01-01), None
patent: WO 96/13497 (1996-05-01), None
patent: 98/38156 (1998-09-01), None
patent: 01/21577 (2001-03-01), None
patent: WO 02/18377 (2002-03-01), None
patent: WO 02/092068 (2002-11-01), None
patent: WO 03/061567 (2003-07-01), None
patent: WO 03/062248 (2003-07-01), None
patent: WO 03/062252 (2003-07-01), None
patent: 03/091219 (2003-11-01), None
patent: 2004/026305 (2004-04-01), None
patent: 2004/113330 (2004-12-01), None
Shen et al, Archiv der Pharmazie, 1995, 328(2), 197-201.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Warrener et al, Journal of the Chemical Society, Chemical Communications (1981), (21), 1100-1.
Wu et al., Toxicology, 236, pp. 1-6, 2007.
Matthew J. Fischer, et al.; “Dihydroisoquinolone RGD MIMICS. Exploration of the Asparate Isostere”; Bioorganic & Medicinal Chemistry Letters; vol. 7 No. 19, pp. 2537-2542; Elsevier Science Ltd., 1997.
Russian Office Action dated Oct. 9, 2009 in Application No. 20070126654.
M.D. Mashkovsky, “Lekarstvennie Sredstva,” Moskva, vol. 1, p. 8 (1993), Partial English Translation.
“Khimicheskii Enciklopedicheskii Slovar,” Moskva, “Sovetskaya Enciklopediya,” pp. 130-131 (1983), Partial English Translation.
Office Action issued on May 3, 2010 in the co-pending U.S. Appl. No. 11/721,601.
Chawla G., et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1; Jan.-Mar. 2004; pp. 9-12.
Newman A. W., et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”; DDT vol. 8, No. 19; Oct. 2003; pp. 898-905.
Nakade S., et al., Caplus an 2005:216595, RN 847585-40-4.
International Search Report dated Feb. 15, 2005.
Habashita Hiromu
Hagiya Hiroshi
Komiya Takaki
Kurata Haruto
Kusumi Kensuke
Davis Zinna N
Ono Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
LandOfFree
Compound capable of binding S1P receptor and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compound capable of binding S1P receptor and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound capable of binding S1P receptor and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240562